The relationship between malignancy and our powerful immune system, long held in our medical and scientific knowledge, has surmised many inadequacies that enable immune drivers and loss of immune regulators of aberrant cellular growth. Recent developments in the field of epidemiological or pharmacological intervention in population cancer risk, epigenetic influences on immune responses, pathogen-driven transformation, molecular and functional immune microenvironmental influences on malignancy, and cytokine-driven aberrant cellular proliferation re-enforce a review and reassessment of this viewpoint. In the age of immune-associated cancer therapeutics, we are further provided a unique opportunity and point of access to re-address this age-old linkage between malignancy and immunity and search for definitive clues as to its ancestry, with malignant prevention being preferable to cure.
This Research Topic will focus on the following cancers and pathogens: Lymphomas, Castlemans syndrome, Hepatocellular carcinoma, Brain malignancies, Burkitt’s Lymphoma, Hodgkin’s Disease, H.Pylori, Epstein-Barr virus (EBV), Hepatitis B virus (HBV), Hepatitis B and C.
We welcome Original Research, Review and Mini-review articles focusing on the following subtopics:
1. Epidemiologic evidence of the immune relationships with malignancy
2. Epigenetic landscape of immunity and malignancy
3. Mechanistic and molecular influences of immune-associated pathways in malignancy
4. Cytokine driven proliferative disorders
5. Pathogen and viral driven malignancy
6. Tumor microenvironmental niche as an immune modulator in malignant transformation
7. Immunological lessens learned from the use of immune-based therapeutics
Manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by robust and relevant validation (clinical cohort or biological validation in vitro or in vivo) are out of scope for this topic.
The relationship between malignancy and our powerful immune system, long held in our medical and scientific knowledge, has surmised many inadequacies that enable immune drivers and loss of immune regulators of aberrant cellular growth. Recent developments in the field of epidemiological or pharmacological intervention in population cancer risk, epigenetic influences on immune responses, pathogen-driven transformation, molecular and functional immune microenvironmental influences on malignancy, and cytokine-driven aberrant cellular proliferation re-enforce a review and reassessment of this viewpoint. In the age of immune-associated cancer therapeutics, we are further provided a unique opportunity and point of access to re-address this age-old linkage between malignancy and immunity and search for definitive clues as to its ancestry, with malignant prevention being preferable to cure.
This Research Topic will focus on the following cancers and pathogens: Lymphomas, Castlemans syndrome, Hepatocellular carcinoma, Brain malignancies, Burkitt’s Lymphoma, Hodgkin’s Disease, H.Pylori, Epstein-Barr virus (EBV), Hepatitis B virus (HBV), Hepatitis B and C.
We welcome Original Research, Review and Mini-review articles focusing on the following subtopics:
1. Epidemiologic evidence of the immune relationships with malignancy
2. Epigenetic landscape of immunity and malignancy
3. Mechanistic and molecular influences of immune-associated pathways in malignancy
4. Cytokine driven proliferative disorders
5. Pathogen and viral driven malignancy
6. Tumor microenvironmental niche as an immune modulator in malignant transformation
7. Immunological lessens learned from the use of immune-based therapeutics
Manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by robust and relevant validation (clinical cohort or biological validation in vitro or in vivo) are out of scope for this topic.